SCHEMBL532567

SCHEMBL532567

Cc1cc(C#N)ccc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 3/20 0.48
GRM5 P41594 2/20 0.47
ALDH1A1 P00352 1/20 0.46
CYP2A6 P11509 1/20 0.46
KIF11 P52732 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
AR P10275 3/20 0.39
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
LMNA P02545 1/20 0.38
HTR7 P34969 1/20 0.38
ACHE P22303 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL100004 0.82 ALDH1A1 (0.46) EGLN2ALDH1A1CYP2A6KIF11AR
SCHEMBL19579054 0.79 EGLN2 (0.50) EGLN2ALDH1A1CYP2A6PDE3BPDE3A
SCHEMBL21881648 0.79 LOXL2 (0.47) GRM5ALDH1A1CYP2A6AR
SCHEMBL2002747 0.79 CTSD (0.45) ALDH1A1CYP2A6GAAARPDE3B
SCHEMBL29416796 0.78 EGLN2 (0.44) EGLN2GRM5ALDH1A1CYP2A6KIF11
SCHEMBL229147 0.78 EGLN2 (0.44) EGLN2GRM5ALDH1A1CYP2A6KIF11
SCHEMBL1436903 0.78 CYP2A6 (0.52) EGLN2ALDH1A1CYP2A6ARFFAR1
SCHEMBL29814587 0.78 CYP2A6 (0.52) EGLN2ALDH1A1CYP2A6ARFFAR1
SCHEMBL21021272 0.78 EGLN2 (0.52) EGLN2ALDH1A1CYP2A6PDE3BPDE3A
SCHEMBL1477519 0.77 GRM5 (0.44) EGLN2GRM5HDAC8ACHEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 502 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720065-A1 PRMT5 INHIBITORS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-04-08 EP disclosed
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 US disclosed
EP-4370207-B1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-12-17 EP disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 WO disclosed
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) 2025-10-23 US disclosed
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 US disclosed
WO-2025149498-A1 BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2025-07-17 WO disclosed
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2025-05-27 US disclosed
EP-4508061-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) 2025-02-19 EP disclosed
CN-119365479-A Conjugates comprising Toll-like receptor agonists 慕宝盛科生物医药(上海)有限公司 2025-01-24 CN disclosed
EP-1708703-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-10-11 EP disclosed
WO-2006083612-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2006-08-10 WO disclosed
US-20060173037-A1 Aminophenyl derivatives as selective androgen receptor modulators ACADIA PHARMACEUTICALS INC. 2006-08-03 US disclosed
WO-2006076317-A2 AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS ACADIA PHARMACEUTICALS INC. (US) 2006-07-20 WO disclosed
US-20060160845-A1 Aminophenyl derivatives as selective androgen receptor modulators ACADIA PHARMACEUTICALS INC. 2006-07-20 US disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 US disclosed
US-20050203078-A1 Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 US disclosed
WO-2005082895-A1 NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-09 WO disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 WO disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK4, CDK2AP2 EGLN2 1148/4885GRM5 3548/4885ALDH1A1 3723/4885
US-20060173037-A1 Aminophenyl derivatives as selective androgen receptor modulators AR, NR5A1, ESRRA EGLN2 1048/4885GRM5 451/4885ALDH1A1 1285/4885
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 EGLN2 3961/4885GRM5 2821/4885ALDH1A1 2998/4885
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 EGLN2 4145/4885GRM5 339/4885ALDH1A1 591/4885
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST TLR3, TLR7, TLR8 EGLN2 4480/4885GRM5 277/4885ALDH1A1 3336/4885
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 EGLN2 1148/4885GRM5 3548/4885ALDH1A1 3723/4885
US-20050277670-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 EGLN2 4161/4885GRM5 471/4885ALDH1A1 3358/4885
US-20060160845-A1 Aminophenyl derivatives as selective androgen receptor modulators AR, NR5A1, ESRRA EGLN2 1048/4885GRM5 451/4885ALDH1A1 1285/4885
US-20050203078-A1 Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide F12, TFPI, F11 EGLN2 3092/4885GRM5 3826/4885ALDH1A1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.